Uterine artery embolization to treat uterine adenomyosis with or without uterine leiomyomata: results of symptom control and health-related quality of life 40 months after treatment

V Froeling, Vera Froeling, Froeling V, Scheurig-Muenkler C, C Scheurig-Muenkler, Christian Scheurig‐Muenkler, Bernd Hamm, B Hamm, Hamm B, T J Kroencke, Thomas Kroencke, Kroencke TJ
Cardiovascular and interventional radiology · 2011 · vol. 35(3) , pp. 523–529 · doi:10.1007/s00270-011-0254-3 · PMID:21850565 · W2102487778
Other OA: closed CC0 ⤵ 27 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite+body, 2026-06-28 ⓘ

Uterine artery embolization effectively treated symptomatic uterine adenomyosis in 72.5% of patients after 40 months, with best results seen in cases of leiomyomata predominance.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 · read from full text ⓘ

This study evaluated long-term outcomes 40 months after uterine artery embolization (UAE) in 40 women aged 39–56 with symptomatic uterine adenomyosis confirmed by magnetic resonance imaging, with or without concomitant uterine leiomyomata. Clinical response was assessed using self-perceived symptom changes, and residual symptom severity and health-related quality of life (HRQOL) were measured, with clinical failure defined as no symptomatic improvement or the need for a second invasive therapy after UAE. UAE achieved symptomatic control in 29 (72.5%) women; 11 underwent hysterectomy or dilatation and curettage for therapy failure, and there was no significant difference between pure adenomyosis versus combined adenomyosis with leiomyomata overall. HRQOL increased and symptom severity decreased after UAE, with the least improvement in women with pure adenomyosis, and the paper relates to endometriosis and adenomyosis research because it focuses on adenomyosis treatment outcomes after UAE.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

PURPOSE: To evaluate the clinical outcome for uterine adenomyosis with or without uterine leiomyomata 40 months after uterine artery embolization (UAE). METHODS: Forty women aged 39-56 years (median 46 years) with symptomatic uterine adenomyosis and magnetic resonance imaging findings of uterine adenomyosis with or without combined uterine leiomyomata underwent UAE. Self-perceived changes in clinical symptoms were assessed, and residual symptom severity and health-related quality of life (HRQOL) after UAE were evaluated. Clinical failure was defined as no symptomatic improvement or second invasive therapy after UAE. Results were stratified by the extent of uterine adenomyosis at baseline magnetic resonance imaging. RESULTS: Patients were followed for a median of 40 months (range 5-102 months). UAE led to symptomatic control after UAE in 29 (72.5%) of 40 patients while 11 women underwent hysterectomy (n=10) or dilatation and curettage (n=1) for therapy failure. No significant difference between women with pure uterine adenoymosis and women with uterine adenomyosis combined with uterine leiomyomata was observed. Best results were shown for UAE in uterine adenomyosis with uterine leiomyomata predominance as opposed to predominant uterine adenomyosis with minor fibroid disease (clinical failure 0% vs. 31.5%, P=0.058). Throughout the study group, HRQOL score values increased and symptom severity scores decreased after UAE. Least improvement was noted for women with pure adenomyosis. CONCLUSIONS: UAE is clinically effective in the long term in most women with uterine adenomyosis. Symptomatic control and HRQOL were highest in patients with combined disease of uterine adenomyosis but leiomyomata predominance.
Full text 6,460 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Purpose To evaluate the clinical outcome for uterine adenomyosis with or without uterine leiomyomata 40 months after uterine artery embolization (UAE).

Methods

Forty women aged 39–56 years (median 46 years) with symptomatic uterine adenomyosis and magnetic resonance imaging findings of uterine adenomyosis with or without combined uterine leiomyomata underwent UAE. Self-perceived changes in clinical symptoms were assessed, and residual symptom severity and health-related quality of life (HRQOL) after UAE were evaluated. Clinical failure was defined as no symptomatic improvement or second invasive therapy after UAE. Results were stratified by the extent of uterine adenomyosis at baseline magnetic resonance imaging.

Results

Patients were followed for a median of 40 months (range 5–102 months). UAE led to symptomatic control after UAE in 29 (72.5%) of 40 patients while 11 women underwent hysterectomy (n = 10) or dilatation and curettage (n = 1) for therapy failure. No significant difference between women with pure uterine adenoymosis and women with uterine adenomyosis combined with uterine leiomyomata was observed. Best results were shown for UAE in uterine adenomyosis with uterine leiomyomata predominance as opposed to predominant uterine adenomyosis with minor fibroid disease (clinical failure 0% vs. 31.5%, P = 0.058). Throughout the study group, HRQOL score values increased and symptom severity scores decreased after UAE. Least improvement was noted for women with pure adenomyosis.

Conclusions

UAE is clinically effective in the long term in most women with uterine adenomyosis. Symptomatic control and HRQOL were highest in patients with combined disease of uterine adenomyosis but leiomyomata predominance. Similar content being viewed by others

References

Matalliotakis IM, Kourtis AI, Panidis DK (2003) Adenomyosis. Obstet Gynecol Clin North Am 30:63–82 Ferenczy A (1998) Pathophysiology of adenomyosis. Hum Reprod Update 4:312–322 Bergeron C, Amant F, Ferency A (2006) Pathology and physiopathology of adenomyosis. Best Pract Res Clin Obstet Gynaecol 20:511–521 Dueholm M, Lundorf E, Hansen ES et al (2001) Magnetic resonance imaging and transvaginal ultrasonography for the diagnosis of adenomyosis. Fertil Steril 76:588–594 Bazot M, Cortez A, Darai E et al (2001) Ultrasonography compared with magnetic resonance imaging for the diagnosis of adenomyosis: correlation with histopathology. Hum Reprod 16:2427–2433 Reinhold C, McCarthy S, Bret PM et al (1996) Diffuse adenomyosis: comparison of endovaginal US and MR imaging with histopathologic correlation. Radiology 199:151–158 Ascher SM, Arnold LL, Patt RH et al (1994) Adenomyosis: prospective comparison of MR imaging and transvaginal sonography. Radiology 190:803–806 Dumousset E, Chabrot P, Rabischong B et al (2008) Preoperative uterine artery embolization (PUAE) before uterine myomectomy. Cardiovasc Intervent Radiol 31:512–520 Goodwin SC, Spies JB (2009) Uterine fibroid embolization. N Engl J Med 361:690–697 Katsumori T, Kasahara T, Kin Y et al (2007) Magnetic resonance angiography of uterine artery: changes with embolization using gelatine sponge particles alone for fibroids. Cardiovasc Intervent Radiol 30:398–404 Spies JB, Bruno J, Czeyda-Pommersheim F et al (2005) Long-term outcome of uterine artery embolization of leiomyomata. Obstet Gynecol 106(5 Pt 1):933–939 McCausland V, McCausland A (1998) The response of adenomyosis to endometrial ablation/resection. Hum Reprod Update 4:350–359 Jha RC, Takahama J, Imaoka I et al (2003) Adenomyosis: MRI of the uterus treated with uterine artery embolization. AJR Am J Roentgenol 181:851–856 Kim MD, Won JW, Lee DY et al (2004) Uterine artery embolization for adenomyosis without fibroids. Clin Radiol 59:520–526 Kitamura Y, Allison SJ, Jha RC et al (2006) MRI of adenomyosis: changes with uterine artery embolization. AJR Am J Roentgenol 186:855–864 Siskin GP, Tublin ME, Stainken BF et al (2001) Uterine artery embolization for the treatment of adenomyosis: clinical response and evaluation with MR imaging. AJR Am J Roentgenol 177:297–302 Lohle PN, De Vries J, Klazen CA et al (2007) Uterine artery embolization for symptomatic adenomyosis with or without uterine leiomyomas with the use of calibrated tris-acryl gelatin microspheres: midterm clinical and MR imaging follow-up. J Vasc Interv Radiol 18:835–841 Spies JB, Coyne K, Guaou Guaou N et al (2002) The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 99:290–300 Gordts S, Brosens JJ, Fusi L et al (2008) Uterine adenomyosis: a need for uniform terminology and consensus classification. Reprod Biomed Online 17:244–248 Bazot M, Lafont C, Rouzier R et al (2009) Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. Fertil Steril 92:1825–1833 Farquhar C, Brosens I (2006) Medical and surgical management of adenomyosis. Best Pract Res Clin Obstet Gynaecol 20:603–616 Fukunishi H, Funaki K, Sawada K et al (2008) Early results of magnetic resonance-guided focused ultrasound surgery of adenomyosis: analysis of 20 cases. J Minim Invasive Gynecol 15:571–579 Bratby MJ, Walker WJ (2009) Uterine artery embolisation for symptomatic adenomyosis—mid-term results. Eur J Radiol 70:128–132 Pelage JP, Jacob D, Fazel A et al (2005) Midterm results of uterine artery embolization for symptomatic adenomyosis: initial experience. Radiology 234:948–953 Kim MD, Kim S, Kim NK et al (2007) Long-term results of uterine artery embolization for symptomatic adenomyosis. AJR Am J Roentgenol 188:176–181 Daraï E, Coutant C, Bazot M et al (2009) Relevance of quality of life questionnaires in women with endometriosis. Gynecol Obstet Fertil 37:240–245 Conflict of interest The authors declare that they have no conflict of interest. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Froeling, V., Scheurig-Muenkler, C., Hamm, B. et al. Uterine Artery Embolization to Treat Uterine Adenomyosis with or without Uterine Leiomyomata: Results of Symptom Control and Health-Related Quality of Life 40 Months after Treatment. Cardiovasc Intervent Radiol 35, 523–529 (2012). https://doi.org/10.1007/s00270-011-0254-3 Received: Accepted: Published: Issue date: DOI: https://doi.org/10.1007/s00270-011-0254-3

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisadenomyosis

MeSH descriptors

Embolization, Therapeutic Endometriosis Quality of Life Quality of Life Adult Adult Chi-Square Distribution Chi-Square Distribution Dilatation and Curettage Dilatation and Curettage Embolization, Therapeutic Embolization, Therapeutic Endometriosis Endometriosis Endometriosis Female Female Humans Humans Hysterectomy

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (27)

Cited by (28)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:09:19.025198+00:00
unpaywall
last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0 · commercial use OK